FindTrial
Sign In

A randomized, double-blind Phase 3 study of S-474474 in patients with essential hypertension, - Evaluation in non-responder to irbesartan -

A randomized, double-blind Phase 3 study of S-474474 in patients with essential hypertension, - Evaluation in non-responder to irbesartan -

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221107
Enrollment
Unknown
Registered
2010-05-21
Start date
2010-05-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

investigational material(s) Generic name etc : S-474474 INN of investigational material : Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational material : or

Sponsors

SHIONOGI & CO., LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with essential hypertension who meet the following criteria: Seated trough systolic blood pressure is not less than140 mmHg, lower than180 mmHg,and seated trough diastolic blood pressure is not less than 90 mmHg, lower than 110 mmHg. etc.

Exclusion criteria

Exclusion criteria: Patients with renal, hepatic or heart disease

Design outcomes

Primary

MeasureTime frame
Change in trough seated diastolic blood pressure—

Secondary

MeasureTime frame
Adverse events and adverse drug reactions, etc—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026